The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 19, 2022

Filed:

Jul. 28, 2017
Applicant:

Biogen Chesapeake Llc, Cambridge, MA (US);

Inventors:

Sven Jacobson, New York, NY (US);

Thomas Macallister, New York, NY (US);

Assignee:

Biogen Chesapeake LLC, Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/64 (2006.01); A61P 25/00 (2006.01); A61K 45/06 (2006.01); A61K 31/7076 (2006.01); A61K 38/49 (2006.01); A61P 25/06 (2006.01); A61K 9/00 (2006.01); A61K 9/70 (2006.01); A61K 31/4045 (2006.01); A61K 38/48 (2006.01); A61N 5/10 (2006.01);
U.S. Cl.
CPC ...
A61K 31/64 (2013.01); A61K 9/0053 (2013.01); A61K 9/7023 (2013.01); A61K 31/4045 (2013.01); A61K 31/7076 (2013.01); A61K 38/482 (2013.01); A61K 38/4893 (2013.01); A61K 38/49 (2013.01); A61K 45/06 (2013.01); A61N 5/1084 (2013.01); A61P 25/00 (2018.01); A61P 25/06 (2018.01); C12Y 304/21068 (2013.01); C12Y 304/21069 (2013.01); C12Y 304/24069 (2013.01);
Abstract

A method of treating or preventing adverse outcomes associated with tissue plasminogen activator (tPA) administration, cerebral edema-related side effects, cerebral edema associated with radiation therapy, or migraine headaches by administering an effective amount of a SUR1-TRPM4 channel inhibitor, such as glyburide, and optionally the co-administration of a second therapeutically active agent, to a subject in need thereof. Adverse outcomes associated with tPA include cerebral hemorrhage, cerebral edema, physical impairment or death. The administration of the SUR1-TRPM4 channel inhibitors occurs prior to the radiation therapy, during the radiation therapy, after the radiation therapy, or combinations thereof. The SUR1-TRPM4 channel inhibitor is administered prior to surgical excision of a brain tumor, CAR-T therapy, or administration of flutarabine. Alternatively, or in addition, the SUR1-TRPM4 channel inhibitor is administered prior the onset of the cerebral edema-related side effects.


Find Patent Forward Citations

Loading…